Dendritic cells (DCs) are the sentinel antigen-presenting cells of the immune system; such
that their productive interface with the dying cancer cells is crucial for proper communication …

Microtubule (MT)‐targeting agents are highly successful drugs as chemotherapeutic agents,
and this is attributed to their ability to target MT dynamics and interfere with critical cellular …

Motivation Identification of novel therapeutic effects for existing US Food and Drug
Administration (FDA)-approved drugs, drug repurposing, is an approach aimed to …

The safety and feasibility of dendritic cell (DC)-based immunotherapies in cancer
management have been well documented after more than twenty-five years of …

Immunogenic cell death is characterized by damage-associated molecular patterns, which
can enhance the maturation and antigen uptake of dendritic cells. Shikonin, an anti …

Immunogenic cell death (ICD) is one of the 12 distinct cell death forms, which can trigger
immune system to fight against cancer cells. During ICD, a number of cellular changes occur …

A growing body of evidence indicates that the anticancer effect of the immune system can be
activated by the immunogenic modulation of dying cancer cells. Cancer cell death, as a …

Apoptosis plays a crucial role in chemotherapy-induced cell death. The conventional theory
holding that apoptosis needs to be immunologically silent has recently been revised, and …

Cancer immune therapy has recently shown tremendous promise to combat many different
cancers. The microtubule is a well-defined and very effective cancer therapeutic target …

Accumulating evidence shows that the anti-cancer potential of the immune response that
can be activated by modulation of the immunogenicity of dying cancer cells. This regulated …